Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

赛马鲁肽 医学 荟萃分析 安慰剂 内科学 2型糖尿病 随机对照试验 置信区间 不利影响 糖尿病 内分泌学 利拉鲁肽 病理 替代医学
作者
Thomas Karagiannis,Konstantinos Malandris,Ioannis Avgerinos,Athina Stamati,Panagiota Kakotrichi,Aris Liakos,Despoina Vasilakou,Nikolaos Kakaletsis,Απόστολος Τσάπας,Eleni Bekiari
出处
期刊:Diabetologia [Springer Science+Business Media]
卷期号:67 (7): 1206-1222 被引量:19
标识
DOI:10.1007/s00125-024-06144-1
摘要

Abstract Aims/hypothesis We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. Methods We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA 1c and body weight from baseline. Secondary outcomes were achievement of HbA 1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework. Results A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (mean difference −21.61 mmol/mol [−1.96%]) followed by tirzepatide 10 mg (−20.19 mmol/mol [−1.84%]), semaglutide 2.0 mg (−17.74 mmol/mol [−1.59%]), tirzepatide 5 mg (−17.60 mmol/mol [−1.60%]), semaglutide 1.0 mg (−15.25 mmol/mol [−1.39%]) and semaglutide 0.5 mg (−12.00 mmol/mol [−1.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia. Conclusions/interpretation Our data show that s.c. tirzepatide had a more pronounced effect on HbA 1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events. Registration PROSPERO registration no. CRD42022382594 Graphical Abstract
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhan20200503完成签到,获得积分10
1秒前
这个文献你有么完成签到,获得积分10
2秒前
小二郎应助lan采纳,获得10
2秒前
李颜龙完成签到,获得积分10
4秒前
liangye2222发布了新的文献求助10
4秒前
与山发布了新的文献求助10
5秒前
5秒前
高手如林完成签到,获得积分10
6秒前
高铭泽完成签到,获得积分20
6秒前
Hengjian_Pu完成签到,获得积分10
6秒前
友好胜完成签到 ,获得积分10
6秒前
坦率白萱发布了新的文献求助10
7秒前
方翔应助林白采纳,获得100
7秒前
量子星尘发布了新的文献求助10
7秒前
Vresty完成签到,获得积分10
9秒前
糯米团的完成签到 ,获得积分10
11秒前
11秒前
Yunsong发布了新的文献求助10
11秒前
黑猫完成签到,获得积分20
12秒前
热心市民小红花应助千余采纳,获得10
13秒前
13秒前
14秒前
lan完成签到,获得积分10
14秒前
火星上念梦发布了新的文献求助150
14秒前
Enckson完成签到,获得积分10
15秒前
火星上的羽毛完成签到,获得积分10
16秒前
留留完成签到,获得积分10
17秒前
lan发布了新的文献求助10
17秒前
我爱金哥发布了新的文献求助10
17秒前
18秒前
小叶曲完成签到,获得积分10
18秒前
21秒前
czl完成签到,获得积分10
24秒前
精明谷发布了新的文献求助10
25秒前
香查朵完成签到,获得积分10
25秒前
lu应助wf采纳,获得10
25秒前
26秒前
Tung完成签到,获得积分10
27秒前
27秒前
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035